Search Tag: MS

Executive Health Management

Know more, treat better

2019 22 May

Affidea applies ground-breaking AI technology on Brain MRI examinations for people with Multiple Sclerosis   Affidea has entered into a partnership with icometrix, a data science company that develops Artificial Intelligence (AI) solutions for healthcare, to standardise and improve the care of patients with neurological disorders. The official... Read more

IT Management

Affidea announces first AI partnership with icometrix to improve care for MS patients

2019 01 Mar

Affidea and icometrix have today announced a strategic partnership to streamline and improve the care of patients with neurological disorders in Europe, with the rollout of a new AI tool for patients with multiple sclerosis (MS).   As the leading European provider of advanced diagnostic imaging services, Affidea is starting the collaboration... Read more

Executive Health Management

2nd MENACTRIMS Congress 2016

2016 17 Mar

MENACTRIMS is an independent organization that facilitates communication and creates synergies among clinicians and scientists to promote and enhance research and improve clinical outcomes in multiple sclerosis (MS). The main objectives of the organization are as follows: To support and promote basic and clinical research in multiple sclerosis in... Read more

IMAGING Management

MRI Shows Grey Matter Demyelination in MS

2014 10 Sep

The severity of myelin loss in the brain’s grey matter is closely related to disease severity in people with multiple sclerosis (MS), according to researchers in the Department of Radiology at the University of Washington, Seattle. The authors of the study, which has been published online in Radiology , used magnetic resonance imaging (MRI) to reveal... Read more

Executive Health Management

Drug For Treatment of Multiple Sclerosis Approved

2013 20 Sep

A transformational new treatment for multiple sclerosis (MS) has been approved by the EU agency responsible for regulating new drugs. This is the result of over three decades of research in Cambridge.  The European Medicines Agency (EMA) has approved the drug Alemtuzumab, to be known by the brand name Lemtrada and previously called Campath-1H... Read more